

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the treatment of chronic heart... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-2134/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-2134" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the treatment of chronic heart failure" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the treatment of chronic heart failure.">
            <meta name="og:description" content="Read the latest article version by Leo F Buckley, Amil M Shah, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="22478">
            <meta name="article-id" content="20447">
            <meta name="dc.title" content="Recent advances in the treatment of chronic heart failure">
            <meta name="dc.description" content="After more than a decade of relatively modest advancements, heart failure therapeutic development has accelerated, with the PARADIGM-HF trial and the SHIFT trial demonstrated significant reductions in cardiovascular death and heart failure hospitalization for sacubitril-valsartan and in heart failure hospitalization alone for ivabradine. Several heart failure therapies have since received or stand on the verge of market approval and promise substantive advances in the treatment of chronic heart failure. Some of these improve clinical outcomes, whereas others improve functional or patient-reported outcomes. In light of these rapid advances in the care of adults living with chronic heart failure, in this review we seek to update the general practitioner on novel heart failure therapies. Specifically, we will review recent data on the implementation of sacubitril-valsartan, treatment of functional mitral regurgitation, sodium-glucose co-transporter-2 (SGLT-2) inhibitor therapy, agents for transthyretin amyloid cardiomyopathy, treatment of iron deficiency in heart failure, and the use of biomarkers or remote hemodynamic monitoring to guide heart failure therapy.">
            <meta name="dc.subject" content="heart failure, therapy">
            <meta name="dc.creator" content="Buckley, Leo F">
            <meta name="dc.creator" content="Shah, Amil M">
            <meta name="dc.date" content="2019/12/20">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.20447.1">
            <meta name="dc.source" content="F1000Research 2019 8:2134">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="heart failure">
            <meta name="prism.keyword" content="therapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/12/20">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="2134">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.20447.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-2134">
            <meta name="citation_title" content="Recent advances in the treatment of chronic heart failure">
            <meta name="citation_abstract" content="After more than a decade of relatively modest advancements, heart failure therapeutic development has accelerated, with the PARADIGM-HF trial and the SHIFT trial demonstrated significant reductions in cardiovascular death and heart failure hospitalization for sacubitril-valsartan and in heart failure hospitalization alone for ivabradine. Several heart failure therapies have since received or stand on the verge of market approval and promise substantive advances in the treatment of chronic heart failure. Some of these improve clinical outcomes, whereas others improve functional or patient-reported outcomes. In light of these rapid advances in the care of adults living with chronic heart failure, in this review we seek to update the general practitioner on novel heart failure therapies. Specifically, we will review recent data on the implementation of sacubitril-valsartan, treatment of functional mitral regurgitation, sodium-glucose co-transporter-2 (SGLT-2) inhibitor therapy, agents for transthyretin amyloid cardiomyopathy, treatment of iron deficiency in heart failure, and the use of biomarkers or remote hemodynamic monitoring to guide heart failure therapy.">
            <meta name="citation_description" content="After more than a decade of relatively modest advancements, heart failure therapeutic development has accelerated, with the PARADIGM-HF trial and the SHIFT trial demonstrated significant reductions in cardiovascular death and heart failure hospitalization for sacubitril-valsartan and in heart failure hospitalization alone for ivabradine. Several heart failure therapies have since received or stand on the verge of market approval and promise substantive advances in the treatment of chronic heart failure. Some of these improve clinical outcomes, whereas others improve functional or patient-reported outcomes. In light of these rapid advances in the care of adults living with chronic heart failure, in this review we seek to update the general practitioner on novel heart failure therapies. Specifically, we will review recent data on the implementation of sacubitril-valsartan, treatment of functional mitral regurgitation, sodium-glucose co-transporter-2 (SGLT-2) inhibitor therapy, agents for transthyretin amyloid cardiomyopathy, treatment of iron deficiency in heart failure, and the use of biomarkers or remote hemodynamic monitoring to guide heart failure therapy.">
            <meta name="citation_keywords" content="heart failure, therapy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Leo F Buckley">
            <meta name="citation_author_institution" content="Department of Pharmacy, Brigham and Women's Hospital, Boston, USA">
            <meta name="citation_author" content="Amil M Shah">
            <meta name="citation_author_institution" content="Department of Pharmacy, Brigham and Women's Hospital, Boston, USA">
            <meta name="citation_author_institution" content="Division of Cardiovascular Medicine, Brigham and Women&rsquo;s Hospital, Boston, USA">
            <meta name="citation_publication_date" content="2019/12/20">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="2134">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.20447.1">
            <meta name="citation_firstpage" content="2134">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-2134/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-2134.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=22478 /> <input type=hidden id=articleId name=articleId value=20447 /> <input type=hidden id=xmlUrl value="/articles/8-2134/v1/xml"/> <input type=hidden id=xmlFileName value="-8-2134-v1.xml"> <input type=hidden id=article_uuid value=3e4a82e9-a09d-4180-8984-bd21341c11f5 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the treatment of chronic heart failure"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.20447.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.20447.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-2134"
  },
  "headline": "Recent advances in the treatment of chronic heart failure",
  "datePublished": "2019-12-20T17:00:19",
  "dateModified": "2019-12-20T17:00:19",
  "author": [
    {
      "@type": "Person",
      "name": "Leo F Buckley"
    },    {
      "@type": "Person",
      "name": "Amil M Shah"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "After more than a decade of relatively modest advancements, heart failure therapeutic development has accelerated, with the PARADIGM-HF trial and the SHIFT trial demonstrated significant reductions in cardiovascular death and heart failure hospitalization for sacubitril-valsartan and in heart failure hospitalization alone for ivabradine. Several heart failure therapies have since received or stand on the verge of market approval and promise substantive advances in the treatment of chronic heart failure. Some of these improve clinical outcomes, whereas others improve functional or patient-reported outcomes. In light of these rapid advances in the care of adults living with chronic heart failure, in this review we seek to update the general practitioner on novel heart failure therapies. Specifically, we will review recent data on the implementation of sacubitril-valsartan, treatment of functional mitral regurgitation, sodium-glucose co-transporter-2 (SGLT-2) inhibitor therapy, agents for transthyretin amyloid cardiomyopathy, treatment of iron deficiency in heart failure, and the use of biomarkers or remote hemodynamic monitoring to guide heart failure therapy."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-2134",
            "name": "Recent advances in the treatment of chronic heart failure"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the treatment of chronic heart failure </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=22478 data-id=20447 data-downloads="" data-views="" data-scholar="10.12688/f1000research.20447.1" data-recommended="" data-doi="10.12688/f1000research.20447.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-2134/v1/pdf?article_uuid=3e4a82e9-a09d-4180-8984-bd21341c11f5" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-20447-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-20447-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-20447-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Buckley LF and Shah AM. Recent advances in the treatment of chronic heart failure [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2134 (<a class=new-orange href="https://doi.org/10.12688/f1000research.20447.1" target=_blank>https://doi.org/10.12688/f1000research.20447.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-20447-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=20447 id=track-article-signin-20447 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/20447?target=/articles/8-2134">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=22478 /> <input name=articleId type=hidden value=20447 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the treatment of chronic heart failure</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Leo F Buckley<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:ashah11@partners.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Amil M Shah</span></a><a href="https://orcid.org/0000-0003-1056-4451" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1056-4451</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Leo F Buckley<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:ashah11@partners.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Amil M Shah</span></a><a href="http://orcid.org/0000-0003-1056-4451" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1056-4451</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 20 Dec 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.20447.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Pharmacy, Brigham and Women's Hospital, Boston, USA<br/> <sup>2</sup> Division of Cardiovascular Medicine, Brigham and Women&rsquo;s Hospital, Boston, USA<br/> <p> <div class=margin-bottom> Leo F Buckley <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation </div> <div class=margin-bottom> Amil M Shah <br/> <span>Roles: </span> Conceptualization, Supervision, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=61683-57912></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=53986-57913></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=61684-57914></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> After more than a decade of relatively modest advancements, heart failure therapeutic development has accelerated, with the PARADIGM-HF trial and the SHIFT trial demonstrated significant reductions in cardiovascular death and heart failure hospitalization for sacubitril-valsartan and in heart failure hospitalization alone for ivabradine. Several heart failure therapies have since received or stand on the verge of market approval and promise substantive advances in the treatment of chronic heart failure. Some of these improve clinical outcomes, whereas others improve functional or patient-reported outcomes. In light of these rapid advances in the care of adults living with chronic heart failure, in this review we seek to update the general practitioner on novel heart failure therapies. Specifically, we will review recent data on the implementation of sacubitril-valsartan, treatment of functional mitral regurgitation, sodium-glucose co-transporter-2 (SGLT-2) inhibitor therapy, agents for transthyretin amyloid cardiomyopathy, treatment of iron deficiency in heart failure, and the use of biomarkers or remote hemodynamic monitoring to guide heart failure therapy. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> heart failure, therapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Amil M Shah (<a href="mailto:ashah11@partners.org">ashah11@partners.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Amil M Shah </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> AMS has received consulting fees from Philips Ultrasound and Bellerophon Therapeutics and research support from Novartis through Brigham and Womens Hospital. LFB declares that he has no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The work for this review was supported by an American College of Clinical Pharmacy Foundation New Investigator Award (LFB); National Heart, Lung, and Blood Institute grants R01HL135008 and R01HL143224 (AMS); and a Watkins Discovery Award from the Brigham and Womens Heart and Vascular Center (AMS). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2019 Buckley LF and Shah AM. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Buckley LF and Shah AM. Recent advances in the treatment of chronic heart failure [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2134 (<a href="https://doi.org/10.12688/f1000research.20447.1" target=_blank>https://doi.org/10.12688/f1000research.20447.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 20 Dec 2019, <b>8</b>(F1000 Faculty Rev):2134 (<a href="https://doi.org/10.12688/f1000research.20447.1" target=_blank>https://doi.org/10.12688/f1000research.20447.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 20 Dec 2019, <b>8</b>(F1000 Faculty Rev):2134 (<a href="https://doi.org/10.12688/f1000research.20447.1" target=_blank>https://doi.org/10.12688/f1000research.20447.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d36773e151>Introduction</h2><p class="" id=d36773e154>After a decade without successful development of novel heart failure therapeutics, the PARADIGM-HF trial and the SHIFT trial demonstrated significant reductions in cardiovascular death and heart failure hospitalization for sacubitril-valsartan and in heart failure hospitalization alone for ivabradine. Since the market introduction of these two therapies, several heart failure therapies have received or stand on the verge of market approval. In light of the rapid advances in the care of adults living with chronic heart failure, we have sought to update the general practitioner on heart failure therapies approved during this wave of successful drug development.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36773e160>Implementation of sacubitril-valsartan</h2><p class="" id=d36773e163>Two clinical trials have tested novel strategies for the safe and effective implementation of sacubitril-valsartan in 498 patients with heart failure and a reduced ejection fraction. The TITRATION study compared the safety and efficacy of conservative and condensed up-titration schedules for sacubitril-valsartan in ambulatory patients<sup><a href="#ref-1">1</a></sup>. All patients received sacubitril-valsartan 24/26 mg twice daily for 5 days during an open-label, run-in period followed by randomization and two additional treatment periods. At randomization, patients in the conservative arm continued sacubitril-valsartan at 24/26 mg twice daily whereas patients in the condensed arm were titrated to 49/51 mg twice daily. After 2 weeks, the conservative arm increased to 49/51 mg twice daily and the condensed arm increased to the maximal dose of 97/103 mg twice daily. The condensed arm then continued the maximal 97/103 mg twice daily for the remaining 9 weeks of the study, whereas the conservative arm continued the 49/51 mg twice-daily regimen for 3 weeks before increasing to the maximal 97/103 mg twice daily for 6 weeks. In aggregate, the condensed arm reached the maximal dose with one fewer visit than the conservative arm and increased from 24/26 mg to 49/51 mg 2 weeks earlier than the conservative arm and from 49/51 mg to 97/103 mg 3 weeks earlier than the conservative arm.</p><p class="" id=d36773e170>The proportion of patients experiencing any hypotension (9.7% vs. 8.4%; <i>P</i> = 0.57) and systolic blood pressure less than 95 mm Hg (8.9% vs. 5.2%; <i>P</i> = 0.10) was not significantly different between the conservative and condensed arms. Serum potassium of more than 5.5 mmol/L occurred in 7.3% of condensed and 4% of conservative patients (<i>P</i> = 0.10). There was no significant difference in renal dysfunction between the two arms (7.3% vs. 7.6%; <i>P</i> = 0.99). Adverse effects occurred most frequently in patients who switched to sacubitril-valsartan from a low dose of an angiotensin-converting enzyme inhibitor (10 mg of enalapril or equivalent) or angiotensin receptor blocker (160 mg of valsartan or equivalent) and those who had baseline systolic blood pressure of 100 to 110 mm Hg. Less than one fifth of patients with heart failure reach target doses of reninangiotensinaldosterone inhibitors.</p><p class="" id=d36773e185>The randomized, double-blind PIONEER-HF trial compared in-hospital initiation of sacubitril-valsartan to initiation or enalapril among 881 patients with stabilized decompensated heart failure<sup><a href="#ref-2">2</a></sup>. Change in N-terminal pro B-type natriuretic peptide (NT-proBNP) from baseline to week 8 was significantly greater in the sacubitril-valsartan group than the enalapril group (geometric mean ratio vs. baseline: 0.53 for sacubitril-valsartan vs. 0.75 for enalapril; between-group percent change: 47% vs. 25%; <i>P</i> &lt;0.001). Sacubitril-valsartan had no effect on a secondary 7-point composite clinical endpoint but was associated with a reduced risk of rehospitalization for heart failure (35 [8%] vs. 61 [14%]; hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.37 to 0.84; <i>P</i> = not reported). Of note, the trial protocol aimed to achieve maximal sacubitril-valsartan doses within 1 week if tolerated. Slightly more patients experienced worsening renal function (13.6% vs. 14.7%), hyperkalemia (11.6% vs. 9.3%), and symptomatic hypotension (15.0% vs. 12.7%) but these differences did not reach statistical significance.</p><p class="" id=d36773e198>These important trials provide clinicians with structured protocols (<a href="#f1">Figure 1</a>) to maximize sacubitril-valsartan doses in hemodynamically stable, normokalemic patients with heart failure and a reduced ejection fraction and relatively intact renal function (estimated glomerular filtration rate of at least 30 mL/min per 1.73 m<sup>2</sup>).</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22478/834e9fdc-aa65-44f2-8556-ce61e9a154d3_figure1.gif"><img alt="834e9fdc-aa65-44f2-8556-ce61e9a154d3_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22478/834e9fdc-aa65-44f2-8556-ce61e9a154d3_figure1.gif"></a><div class=caption><h3>Figure 1. Titration schedules for ambulatory and hospitalized patients initiating sacubitril-valsartan.</h3></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36773e225>Sacubitril-valsartan for the treatment of heart failure with preserved ejection fraction</h2><p class="" id=d36773e228>The PARAGON-HF trial tested the hypothesis that sacubitril-valsartan lowers the rate of a composite outcome of total heart failure hospitalizations and cardiovascular death compared with valsartan alone in patients with heart failure and preserved ejection fraction<sup><a href="#ref-3">3</a></sup>. In addition to a left ventricular ejection fraction (LVEF) of at least 45%, patients were required to have additional objective criteria of heart failure, including an elevated natriuretic peptide level, structural heart disease (left atrial enlargement or increased left ventricular wall thickness), and diuretic use. Patients were ineligible if they had a previous LVEF of less than 40%. After a single-blind run-in phase, 4796 patients were randomly assigned to sacubitril-valsartan (target dose of 97/103 mg twice daily) or valsartan (target dose of 160 mg twice daily) and followed for a median of 35 (interquartile range of 30 to 41) months.</p><p class="" id=d36773e235>The number of composite heart failure hospitalizations or cardiovascular deaths was nominally lower in the sacubitril-valsartan arm than in the valsartan arm (526 vs. 1009; rate ratio 0.87, 95% CI 0.75 to 1.01; <i>P</i> = 0.06) but did not achieve statistical significance. Randomization to sacubitril-valsartan was associated with a smaller total number of heart failure hospitalizations (690 vs. 797; rate ratio 0.85, 95% CI 0.72 to 1.00) but no difference in death due to cardiovascular causes (204 [8.5%] vs. 212 [8.9%] in the sacubitril-valsartan and valsartan arms respectively) or due to any cause (342 [14.1%] vs. 349 [14.6%]). Although New York Heart Association functional class remains unchanged at 8 months in most patients, more sacubitril-valsartan patients than valsartan patients appeared to have investigator-assessed improvements in functional class (347 [15%] vs. 289 [12.6%]; <i>P</i> = not reported due to hierarchical analysis plan). Hypotension with systolic blood pressure of less than 100 mm Hg and elevations in serum creatinine of at least 2.0 mg/dL occurred less frequently in the sacubitril-valsartan arm, whereas angioedema occurred more frequently in the sacubitril-valsartan arm (14 [0.6%] vs. 4 [0.2%], <i>P</i> = 0.02). The investigators concluded that sacubitril-valsartan did not reduce the rate of a composite outcome of total heart failure hospitalizations and cardiovascular deaths compared with valsartan in patients with heart failure and preserved ejection fraction. Furthermore, any potential beneficial treatment effect appeared restricted to heart failure hospitalization and not cardiovascular mortality. The use of valsartan as an active comparator was consistent with most participants pre-enrollment treatment regimens but may have diminished any potential between-group differences.</p><p class="" id=d36773e247>In pre-specified subgroup analyses, significant heterogeneity of effect was observed by qualifying LVEF and gender. Sacubitril-valsartan reduced the primary composite outcome in patients with an ejection fraction below the median of 57% (rate ratio 0.78, 95% CI 0.64 to 0.95) but not those with an ejection fraction above the median of 57% (rate ratio 1.00, 95% CI 0.81 to 1.23) and among women (rate ratio 0.73, 95% CI 0.59 to 0.90) but not men (rate ratio 1.03, 95% CI 0.85 to 1.25). Although the results of pre-specified subgroup analyses in an overall neutral trial must be considered with caution, the intriguing interactions by LVEF and gender may prove to be significant for several reasons. Patients who have a preserved but modestly depressed ejection fraction may be phenotypically more similar to those with a markedly reduced than robustly preserved ejection fraction<sup><a href="#ref-4">4</a></sup>. Sacubitril-valsartan has proven benefits in patients with an ejection fraction of less than 40%<sup><a href="#ref-5">5</a></sup>. Moreover, post-hoc analyses of spironolactone<sup><a href="#ref-6">6</a></sup> and candesartan<sup><a href="#ref-7">7</a></sup> clinical trials suggest a benefit for these therapies in patients with a mid-range ejection fraction. The effect modification of gender merits further research. Although this unexpected finding may be attributable to chance, the known biological differences between men and women provide multiple potential explanations for future investigation. In addressing one question, PARAGON-HF has not only advanced our understanding of heart failure with preserved ejection fraction but also highlighted several areas for future research. It will be interesting to see whether guidelines incorporate the results of PARAGON-HF in a manner consistent with TOPCAT, as American guidelines give spironolactone a IIb recommendation for decreasing hospitalizations<sup><a href="#ref-8">8</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36773e273>Treatment of secondary mitral regurgitation</h2><p class="" id=d36773e276>Although secondary mitral regurgitation due to left ventricular dysfunction confers an increased risk of hospitalization and death, treatment options remain limited as surgical repair or replacement does not improve clinical outcomes<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>. The MitraClip is a percutaneous device that reduces mitral regurgitation severity by facilitating approximation of the anterior and posterior mitral valve leaflets<sup><a href="#ref-11">11</a></sup>. The efficacy and safety of mitral valve repair with the MitraClip were studied in two clinical trials with similar designs.</p><p class="" id=d36773e290>MITRA-FR (N = 304) and COAPT (N = 614) were randomized comparisons of mitral valve repair with the MitraClip plus guideline-directed medical therapy versus guideline-directed medical therapy alone<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>. Although both trials enrolled patients with at least moderate to severe regurgitation, COAPT targeted a population of patients with a larger effective orifice regurgitant area (30 vs. 20 mm<sup>2</sup>) or a larger regurgitant volume (&gt;45 vs. &gt;30 mL) and less severe left ventricular dysfunction (LVEF 20 to 50% vs. 15 to 40% and left ventricular end-systolic diameter of not more than 70 mL in COAPT vs. no restriction in MITRA-FR). Thus, the contribution of mitral regurgitation to heart failure symptoms relative to myocardial dysfunction may have been greater in COAPT than MITRA-FR. In addition, COAPT patients were enrolled after optimization of guideline-directed medical therapy.</p><p class="" id=d36773e303>In MITRA-FR, mitral valve repair with the MitraClip had no significant effect on the primary endpoint of all-cause death or heart failure hospitalization at 12 months (54.6% vs. 51.3% for repair vs. usual care; HR 1.16, 95% CI 0.73 to 1.83; <i>P</i> = 0.53). In contrast, in the COAPT trial, mitral valve repair with the MitraClip significantly reduced the risk of the primary endpoint of heart failure hospitalization at 24 months (35.8% vs. 67.9%; HR 0.53, 95% CI 0.40 to 0.70; <i>P</i> &lt;0.001) and the composite of all-cause death or heart failure hospitalization (<i>P</i> &lt;0.001).</p><p class="" id=d36773e315>Pharmacologic treatment with sacubitril-valsartan may also reduce mitral valve regurgitation, although the effects on clinical outcomes remain unclear. In the PRIME trial, patients with heart failure and mitral valve regurgitation who were randomly assigned to sacubitril-valsartan had significantly greater reductions in effective orifice regurgitant area (0.06  0.10 vs. 0.02  0.10 cm<sup>2</sup>; <i>P</i> = 0.03) and regurgitant volume (4.3  15.1 vs. 11.6  14.4 mL; <i>P</i> = 0.009) than those randomly assigned to valsartan. One (2%) death and three (5%) heart failure events occurred in the sacubitril-valsartan group versus zero and five (9%) in the valsartan group (<i>P</i> &gt;0.49 for each).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36773e333>SGLT-2 inhibitors and heart failure</h2><p class="" id=d36773e336>The risk of incident heart failure in patients with type 2 diabetes mellitus (T2DM) is twofold greater than that of patients without T2DM<sup><a href="#ref-14">14</a></sup>. Moreover, the presence of T2DM is associated with a poor prognosis among patients with heart failure<sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d36773e347>About 90% of tubular glucose reabsorption occurs through the tubular sodium-glucose co-transporter-2 (SGLT-2)<sup><a href="#ref-15">15</a></sup>. SGLT-2 inhibitors therefore lower blood glucose concentrations by enhancing glucosuria. SGLT-2 inhibition also induces durable weight loss (primarily a reduction in fat mass and not in lean mass) and lowers blood pressure<sup><a href="#ref-16">16</a></sup>.</p><p class="" id=d36773e358>Secondary and post-hoc analyses of three clinical trials provide strong evidence that SGLT-2 inhibitors modulate heart failure outcomes in patients with T2DM. Three SGLT-2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) significantly reduce the composite of heart failure hospitalization or cardiovascular death<sup><a href="#ref-17">17</a><a href="#ref-19">19</a></sup>. Whereas the beneficial effects of empagliflozin were consistent between patients with and without a history of heart failure at baseline<sup><a href="#ref-20">20</a></sup>, canagliflozin and dapagliflozin demonstrated larger effect sizes in patients with a history of heart failure<sup><a href="#ref-21">21</a><a href="#ref-23">23</a></sup>.</p><p class="" id=d36773e379>Small observational studies suggest that treatment of T2DM (with or without heart failure) with SGLT-2 inhibitors improves left ventricular filling pressure, as measured by E/e ratio and left atrial volume index<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>. The molecular mechanisms through which SGLT-2 inhibition may modulate cardiac structure and function remain under investigation. Hypothesized mechanisms include altered myocardial metabolism and energetics, glucosuria-induced diuresis without concomitant reninangiotensinaldosterone system activation, and inhibition of the myocardial sodium-hydrogen transporter<sup><a href="#ref-10">10</a></sup>.</p><p class="" id=d36773e394>Most recently, the DAPA-HF trial extended the benefits of SGLT-2 inhibitors from patients with T2DM to heart failure with reduced LVEF patients without T2DM<sup><a href="#ref-26">26</a></sup>. This trial randomly assigned 4744 patients with symptomatic heart failure and an ejection fraction of less than 40% to receive dapagliflozin 10 mg once daily or placebo, in addition to background heart failure therapy. The primary endpoint was hospitalization or urgent visit for heart failure or cardiovascular death. Most patients (58%) did not have a history of diabetes mellitus at baseline. The mean LVEF and the median NT-proBNP level at baseline were approximately 31  7% and 1400 (857 to 2650) pg/mL, respectively. Use of guideline-directed medical therapy was high, including angiotensin-converting enzyme inhibitor (56%), angiotensin receptor blocker (27%) or sacubitril-valsartan (11%), a beta-blocker (96%), and mineralocorticoid receptor antagonist (71%).</p><p class="" id=d36773e401>After a median follow-up duration of 18.2 months, patients randomly assigned to dapagliflozin experienced significantly fewer primary composite events than those randomly assigned to placebo (16.3% vs. 21.2%; HR 0.74, 95% CI 0.65 to 0.85; <i>P</i> &lt;0.001). Dapagliflozin also reduced the incidence of each of the individual components of the primary outcome. Furthermore, the benefits of dapagliflozin did not significantly differ between patients with (HR 0.75, 95% CI 0.63 to 0.90) and without (HR 0.73, 95% CI 0.60 to 0.88) T2DM at baseline (<i>P</i> interaction = not reported). As expected, hypoglycemia requiring intervention occurred infrequently (4/2368 [0.2%]) in the dapagliflozin arm. There were no significant differences in amputations, diabetic ketoacidosis, or renal adverse events. These exciting results have re-positioned SGLT-2 inhibitors as a complete cardiometabolic, rather than glucose-lowering, therapy.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36773e414>Transthyretin amyloid cardiomyopathy</h2><p class="" id=d36773e417>Aggregation of misfolded transthyretin monomers into amyloid fibrils and subsequent tissue deposition lead to tissue dysfunction<sup><a href="#ref-27">27</a></sup>. Myocardial infiltration of amyloid fibrils can cause heart failure by interfering with cardiac contractility and relaxation as well as through direct toxicity of the amyloid fibrils. Transthyretin amyloid cardiomyopathy may represent up to 12% of all cases of heart failure with preserved ejection fraction<sup><a href="#ref-28">28</a></sup>. Until the development of transthyretin stabilizers and RNA therapeutics, transthyretin amyloid cardiomyopathy treatment focused on symptom palliation and there was minimal impetus to diagnose this debilitating condition.</p><div class=section><a name=d36773e428 class=n-a></a><h3 class=section-title>Tafamidis</h3><p class="" id=d36773e433>Tafamidis is a synthetic small molecule that binds to the thyroxine-binding sites on transthyretin<sup><a href="#ref-29">29</a></sup>. In adults with either wild-type or hereditary transthyretin amyloid cardiomyopathy, tafamidis significantly reduced the risk of all-cause mortality and cardiovascular hospitalization in the randomized, double-blind, placebo-controlled ATTR-ACT study<sup><a href="#ref-30">30</a></sup>. Of the 441 patients of ATTR-ACT, 71% (n = 186) of tafamidis patients were living compared with 57% (n = 101) of placebo patients at 32 months (win ratio 1.70, 95% CI 1.26 to 2.29; <i>P</i> &lt;0.001). Cardiovascular hospitalization occurred in 138 tafamidis patients (52%; 0.48 per patient-year) compared with 107 placebo patients (61%; 0.70 per patient-year) (relative risk ratio 0.68, 95% CI 0.56 to 0.81; <i>P</i> = not reported).</p><p class="" id=d36773e450>The effects of tafamidis were consistent across transthyretin genotypes (for those with hereditary transthyretin amyloid cardiomyopathy) and both the 80 mg and 20 mg tafamidis doses. Delayed worsening heart failure symptoms and declining exercise capacity were observed in the tafamidis arms as early as 6 months, whereas the mortality benefit emerged after 18 months. ATTR-ACT was not powered to detect statistically significant improvements in left ventricular structure and function, although favorable trends were observed in left ventricular wall thickness and left ventricular global longitudinal strain. The incidence of serious adverse events was not significantly different between tafamidis and placebo.</p></div><div class=section><a name=d36773e454 class=n-a></a><h3 class=section-title>Patisiran</h3><p class="" id=d36773e459>Patisiran is a small, interfering RNA<sup><a href="#ref-31">31</a></sup> encapsulated within a liposome that targets a conserved sequence in the 3 untranslated region of wild-type and mutant transthyretin mRNA, thereby suppressing gene expression via the RNA-induced silencing complex<sup><a href="#ref-32">32</a></sup>. Patisiran 0.3 mg/kg every 3 weeks decreased serum transthyretin levels by 81% and improved neuropathy, as measured by the modified Neuropathy Impairment Score + 7 in 225 patients with hereditary transthyretin amyloidosis enrolled in the randomized, double-blind, placebo-controlled APOLLO study (N = 225)<sup><a href="#ref-33">33</a></sup>.</p><p class="" id=d36773e474>Transthoracic two-dimensional echocardiography was performed in 126 (56%) APOLLO patients with left ventricular wall thickness of at least 13 mm and no history of aortic valve disease or hypertension<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>. Mean left ventricular wall thickness (least squares mean difference [LSMD]  standard error of the mean [SEM], 0.9  0.4; <i>P</i> = 0.017) and left ventricular end-diastolic volume (LSEM  SEM, 5.1  1.9 vs. 13.4  3.4; <i>P</i> = 0.036) each decreased to a greater extent in the patisiran arm compared with placebo at 18 months. Patisiran improved left ventricular absolute global longitudinal strain by 1.4% (95% CI 0.3 to 0.5%; <i>P</i> = 0.02) versus placebo. Absolute basal, midwall and apical longitudinal strains also improved with patisiran treatment with basal longitudinal strain reaching statistical significance. In an exploratory post-hoc analysis of clinical outcomes, patisiran was associated with a trend toward lower risk of cardiac death or hospitalization compared with placebo (10.1 vs. 18.7 events per 100 patient-years; HR 0.54, 95% CI 0.28 to 1.01).</p></div><div class=section><a name=d36773e494 class=n-a></a><h3 class=section-title>Clinical implementation</h3><p class="" id=d36773e499>Tafamidis was approved by the US Food and Drug Administration for the treatment of wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy in 2019, whereas patisiran was approved for the treatment of hereditary transthyretin amyloid polyneuropathy, but not amyloid cardiomyopathy, in 2018. Both agents have a considerable cost of tens or hundreds of thousands of dollars annually. Thus, patisiran is unlikely to be covered by payers for the treatment of amyloid cardiomyopathy and tafamidis is unlikely to be covered for the treatment of polyneuropathy. Tafamidis is the preferred agent for patients with amyloid cardiomyopathy.</p><p class="" id=d36773e502>The effects of a second RNA therapeutic, inotersen<sup><a href="#ref-36">36</a></sup>, and a second transthyretin tetramer stabilizer, AG10<sup><a href="#ref-37">37</a></sup>, on cardiac structure and function in adults with transthyretin amyloid cardiomyopathy are unclear.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36773e517>Iron deficiency</h2><p class="" id=d36773e520>Depending upon the definition, iron deficiency (with or without anemia) affects up to 50% of adults with chronic heart failure<sup><a href="#ref-38">38</a><a href="#ref-40">40</a></sup> and is associated with poor prognosis<sup><a href="#ref-41">41</a></sup>, impaired exercise capacity and skeletal muscle function<sup><a href="#ref-42">42</a>,<a href="#ref-43">43</a></sup>, and worse quality of life<sup><a href="#ref-44">44</a></sup>. Patients with heart failure have decreased myocardial iron content<sup><a href="#ref-45">45</a></sup>, and iron-deficient cardiomyocytes have impaired contractility<sup><a href="#ref-46">46</a></sup> and mitochondrial dysfunction<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. Iron repletion with intravenous iron improves quality of life and may prevent heart failure hospitalizations in patients with heart failure and iron deficiency, irrespective of anemia status<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. In 2017, three clinical trials addressed important unanswered questions related to iron repletion in adults with heart failure, namely the effect of iron repletion on exercise capacity as measured by peak oxygen consumption<sup><a href="#ref-50">50</a></sup>, the effect of iron repletion on peripheral skeletal muscle function<sup><a href="#ref-51">51</a></sup>, and the role of oral iron supplements in patients with heart failure and iron deficiency<sup><a href="#ref-52">52</a></sup>.</p><div class=section><a name=d36773e580 class=n-a></a><h3 class=section-title>Effect of ferric carboxymaltose on exercise capacity in patients with iron deficiency and chronic heart failure (EFFECT-HF)</h3><p class="" id=d36773e585>EFFECT-HF randomly assigned 172 adults with symptomatic heart failure with reduced ejection fraction and iron deficiency (defined as serum ferritin of less than 100 ng/mL or serum ferritin 100 to 300 ng/mL with a transferrin saturation of less than 20%) to receive ferric carboxymaltose, dose-adjusted to target hemoglobin, ferritin, and transferrin saturation levels, or usual care for 24 weeks<sup><a href="#ref-49">49</a></sup>. At 24 weeks, peak oxygen consumption decreased to a greater extent in the usual care arm than the ferric carboxymaltose arm (LSMD  SEM, 1.0  0.4 mL<b></b>kg<sup>1</sup><b></b>min<sup>1</sup>; <i>P</i> = 0.02). There were no between-group differences in ventilatory efficiency, as measured by the slope of the carbon dioxideminute ventilation relationship, or treatment effect differences between patients with and without concomitant anemia.</p><p class="" id=d36773e606>Thus, EFFECT-HF was the first trial to demonstrate an improvement in exercise capacity using gas-exchange variables rather than the 6-minute walk test. In their joint 2017 focused update of the Guideline for the Management of Heart Failure, the American College of Cardiology Foundation and the American Heart Association gave intravenous iron replacement to improve function status and quality of life a weak recommendation (IIb) based upon moderate-quality evidence (B-R)<sup><a href="#ref-8">8</a></sup>. EFFECT-HF was not included in the focused guideline update.</p></div><div class=section><a name=d36773e614 class=n-a></a><h3 class=section-title>Ferric iron in heart failure II (FERRIC-HF II)</h3><p class="" id=d36773e619>FERRIC-HF was a randomized, double-blind, placebo-controlled clinical trial of 40 patients with symptomatic heart failure with reduced ejection fraction, iron deficiency (defined as serum ferritin of less than 100 ng/mL or serum ferritin 100 to 300 ng/mL with a transferrin saturation of less than 20%), and normal folate and vitamin B<sub>12</sub> levels<sup><a href="#ref-51">51</a></sup>. Patients randomly received iron isomaltoside (the total dose was calculated by using the Ganzoni formula) or matching placebo. The primary endpoint was phosphocreatine recovery half-time on dynamic 31P magnetic resonance spectroscopy during submaximal exercise, where a shorter half-life indicates faster phosphocreatine recovery and improved mitochondrial oxidative function.</p><p class="" id=d36773e629>At 2 weeks, phosphocreatine half-time was 6.8 seconds (95% CI 11.5 to 2.1; <i>P</i> = 0.006) shorter in the iron isomaltoside group than the placebo group. Iron isomaltoside also improved adenosine diphosphate recovery half-time but had no effect on resting or end-exercise phosphocreatine or adenosine diphosphate half-time. This study provides important mechanistic insight into the pleiotropic effects of iron repletion in heart failure.</p></div><div class=section><a name=d36773e636 class=n-a></a><h3 class=section-title>Iron repletion effects on oxygen uptake in heart failure (IRONOUT HF)</h3><p class="" id=d36773e641>In IRONOUT HF, 225 patients with symptomatic heart failure with reduced ejection fraction and iron deficiency (defined as serum ferritin of less than 100 ng/mL or serum ferritin 100 to 300 ng/mL with a transferrin saturation of less than 20%) were randomly assigned to receive iron polysaccharide 150 mg twice daily for 16 weeks<sup><a href="#ref-52">52</a></sup>. Oral iron supplementation with iron polysaccharide had no effect on peak oxygen consumption, ventilatory efficiency, 6-minute walk distance, or heart failure symptoms. Notably, iron polysaccharide had minimal effects on serum ferritin (median change from baseline of 18 ng/mL, 95% CI 8 to 38) and transferrin saturation (median change from baseline of 2%, 95% CI 3 to 7%). <a href="#f2">Figure 2</a> compares changes in serum ferritin and transferrin saturation between oral and intravenous iron repletion regimens in patients with heart failure at multiple time points. Subgroup analyses suggest that iron repletion was greater among patients with lower levels of hepcidin, an iron regulatory protein that decreases enteral iron absorption and sequesters iron intracellularly.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22478/834e9fdc-aa65-44f2-8556-ce61e9a154d3_figure2.gif"><img alt="834e9fdc-aa65-44f2-8556-ce61e9a154d3_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22478/834e9fdc-aa65-44f2-8556-ce61e9a154d3_figure2.gif"></a><div class=caption><h3>Figure 2. Comparison of iron repletion regimens in patients with heart failure.</h3></div></div><p class="" id=d36773e665>Future studies should determine whether different oral iron regimens can replete iron stores in patients with heart failure. Studies of women with anemia suggest that frequent oral iron administration induces an increase in hepcidin levels and that less frequent oral supplementation (for example, once daily on three days of the week) paradoxically may improve iron repletion<sup><a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36773e679>Biomarker-guided heart failure therapy</h2><p class="" id=d36773e682>The natriuretic peptide B-type natriuretic peptide (BNP) and its congener N-terminal-proBNP (NT-proBNP) provide considerable diagnostic and prognostic value in heart failure<sup><a href="#ref-19">19</a></sup>. Yet the value of natriuretic peptideguided heart failure management remains unclear. A meta-analysis of 2000 participants across 11 clinical trials demonstrated significant reductions in all-cause mortality (HR 0.62, 95% CI 0.45 to 0.86; <i>P</i> = 0.004), heart failure hospitalization (HR 0.80, 95% CI 0.67 to 0.94; <i>P</i> = 0.009), and cardiovascular hospitalization (HR 0.82, 95% CI 0.67 to 0.99; <i>P</i> = 0.048) with natriuretic peptideguided heart failure management<sup><a href="#ref-54">54</a></sup>. In contrast, the GUIDE-IT trial (N = 894) found no difference in time to first heart failure hospitalization or cardiovascular death between patients randomly assigned to an NT-proBNPguided strategy and usual care<sup><a href="#ref-55">55</a></sup>.</p><p class="" id=d36773e707>An exploratory, post-hoc analysis of the neutral TIME-CHF trial used the gap-time method to compare NT-proBNPguided therapy with usual care to account for recurrent events<sup><a href="#ref-56">56</a></sup>. While NT-proBNPguided therapy was associated with reduced second all-cause hospitalizations, there was no effect on the second heart failure hospitalization. In the subgroup of patients younger than 75 years, guided therapy was associated with reduced first and second all-cause and heart failure hospitalizations. Current guidelines do not recommend natriuretic peptideguided therapy<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup>.</p><p class="" id=d36773e721>Carbohydrate antigen 125 is a glycoprotein associated with prognosis in acute heart failure. In a multicenter clinical trial of 380 patients, carbohydrate antigen 125guided therapy significantly reduced the composite of death or heart failure hospitalization at 1 year. Replication of these results would provide compelling support for carbohydrate antigen 125guided therapy.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36773e727>Remote hemodynamic monitoring-guided heart failure therapy</h2><p class="" id=d36773e730>Titration of guideline-recommended medical therapy to a target pulmonary artery diastolic pressure, estimated using an implantable hemodynamic monitor, reduces heart failure hospitalizations by 28% in patients with reduced and preserved ejection fraction<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>. Recent analyses have provided additional insights into the efficacy and safety of remote hemodynamic monitoring. First, the findings of the CHAMPION trial have been replicated in two separate analysis of routinely collected clinical data<sup><a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>. Second, review of medication titration patterns during the CHAMPION trial has demonstrated that diuretic adjustments and (among patients with heart failure and a reduced ejection fraction) guideline-directed medical therapy adjustments contributed to the reduced hospitalization rates<sup><a href="#ref-63">63</a>,<a href="#ref-64">64</a></sup>. Third, individual practices have begun to report their experience with the implementation and maintenance of a remote hemodynamic monitoring program<sup><a href="#ref-65">65</a><a href="#ref-67">67</a></sup>. These practice-based insights will prove useful as additional remote monitoring devices reach the market. Last, comparative effectiveness studies suggest that remote hemodynamic monitoring meets currently accepted thresholds for cost-effectiveness but the overall budget impact may be difficult to absorb<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>. Ongoing research is investigating the role of remote hemodynamic monitoring in patients with mechanical circulatory support devices and the effects of novel heart failure therapies on pulmonary artery pressure<sup><a href="#ref-70">70</a><a href="#ref-72">72</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36773e779>Conclusions</h2><p class="" id=d36773e782>After more than a decade of relatively modest advancements, heart failure therapeutic development has accelerated and led to several advances in the treatment of chronic heart failure. Some of these new technologies improved clinical outcomes, whereas others improve functional or patient-reported outcomes.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d36773e789 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d37287>References</h2><div class="section ref-list"><a name=d36773e789 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d36773e796 class=n-a></a>Senni M, McMurray JJ, Wachter R, <i> et al.</i>: Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <i>Eur J Heart Fail.</i> 2016; <b>18</b>(9): 1193202. <a target=xrefwindow id=d36773e807 href="http://www.ncbi.nlm.nih.gov/pubmed/27170530">PubMed Abstract </a> | <a target=xrefwindow id=d36773e810 href="https://doi.org/10.1002/ejhf.548">Publisher Full Text </a> | <a target=xrefwindow id=d36773e814 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5084812">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734412731"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e823 class=n-a></a>Velazquez EJ, Morrow DA, DeVore AD, <i> et al.</i>: Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. <i>N Engl J Med.</i> 2019; <b>380</b>(6): 539548. <a target=xrefwindow id=d36773e834 href="http://www.ncbi.nlm.nih.gov/pubmed/30415601">PubMed Abstract </a> | <a target=xrefwindow id=d36773e837 href="https://doi.org/10.1056/NEJMoa1812851">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734412731">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736522882"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e850 class=n-a></a>Solomon SD, McMurray JJV, Anand IS, <i> et al.</i>: Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>N Engl J Med.</i> 2019; <b>381</b>(17): 16091620. <a target=xrefwindow id=d36773e861 href="http://www.ncbi.nlm.nih.gov/pubmed/31475794">PubMed Abstract </a> | <a target=xrefwindow id=d36773e864 href="https://doi.org/10.1056/NEJMoa1908655">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736522882">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d36773e877 class=n-a></a>Hsu JJ, Ziaeian B, Fonarow GC: Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. <i>JACC Heart Fail.</i> 2017; <b>5</b>(11): 763771. <a target=xrefwindow id=d36773e885 href="http://www.ncbi.nlm.nih.gov/pubmed/29032140">PubMed Abstract </a> | <a target=xrefwindow id=d36773e888 href="https://doi.org/10.1016/j.jchf.2017.06.013">Publisher Full Text </a> | <a target=xrefwindow id=d36773e891 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6668914">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d36773e900 class=n-a></a>McMurray JJ, Packer M, Desai AS, <i> et al.</i>: Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>N Engl J Med.</i> 2014; <b>371</b>(11): 9931004. <a target=xrefwindow id=d36773e911 href="http://www.ncbi.nlm.nih.gov/pubmed/25176015">PubMed Abstract </a> | <a target=xrefwindow id=d36773e914 href="https://doi.org/10.1056/NEJMoa1409077">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725792275"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e924 class=n-a></a>Solomon SD, Claggett B, Lewis EF, <i> et al.</i>: Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <i>Eur Heart J.</i> 2016; <b>37</b>(5): 45562. <a target=xrefwindow id=d36773e935 href="http://www.ncbi.nlm.nih.gov/pubmed/26374849">PubMed Abstract </a> | <a target=xrefwindow id=d36773e938 href="https://doi.org/10.1093/eurheartj/ehv464">Publisher Full Text </a> | <a target=xrefwindow id=d36773e942 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4751235">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725792275">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d36773e955 class=n-a></a>Lund LH, Claggett B, Liu J, <i> et al.</i>: Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>Eur J Heart Fail.</i> 2018; <b>20</b>(8): 12301239. <a target=xrefwindow id=d36773e966 href="http://www.ncbi.nlm.nih.gov/pubmed/29431256">PubMed Abstract </a> | <a target=xrefwindow id=d36773e969 href="https://doi.org/10.1002/ejhf.1149">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d36773e978 class=n-a></a>Yancy CW, Jessup M, Bozkurt B, <i> et al.</i>: 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>J Am Coll Cardiol.</i> 2017; <b>70</b>(6): 776803. <a target=xrefwindow id=d36773e989 href="http://www.ncbi.nlm.nih.gov/pubmed/28461007">PubMed Abstract </a> | <a target=xrefwindow id=d36773e992 href="https://doi.org/10.1016/j.jacc.2017.04.025">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d36773e1001 class=n-a></a>Asgar AW, Mack MJ, Stone GW: Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. <i>J Am Coll Cardiol.</i> 2015; <b>65</b>(12): 12311248. <a target=xrefwindow id=d36773e1009 href="http://www.ncbi.nlm.nih.gov/pubmed/25814231">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1012 href="https://doi.org/10.1016/j.jacc.2015.02.009">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d36773e1021 class=n-a></a>Nishimura RA, Otto CM, Bonow RO, <i> et al.</i>: 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol.</i> 2017; <b>70</b>(2): 252289. <a target=xrefwindow id=d36773e1032 href="http://www.ncbi.nlm.nih.gov/pubmed/28315732">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1035 href="https://doi.org/10.1016/j.jacc.2017.03.011">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/10118956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1044 class=n-a></a>Feldman T, Foster E, Glower DD, <i> et al.</i>: Percutaneous repair or surgery for mitral regurgitation. <i>N Engl J Med.</i> 2011; <b>364</b>(15): 1395406. <a target=xrefwindow id=d36773e1055 href="http://www.ncbi.nlm.nih.gov/pubmed/21463154">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1058 href="https://doi.org/10.1056/NEJMoa1009355">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/10118956">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733874366"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1072 class=n-a></a>Obadia JF, Messika-Zeitoun D, Leurent G, <i> et al.</i>: Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. <i>N Engl J Med.</i> 2018; <b>379</b>(24): 22972306. <a target=xrefwindow id=d36773e1083 href="http://www.ncbi.nlm.nih.gov/pubmed/30145927">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1086 href="https://doi.org/10.1056/NEJMoa1805374">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733874366">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734059120"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1099 class=n-a></a>Stone GW, Lindenfeld J, Abraham WT, <i> et al.</i>: Transcatheter Mitral-Valve Repair in Patients with Heart Failure. <i>N Engl J Med.</i> 2018; <b>379</b>(24): 23072318. <a target=xrefwindow id=d36773e1110 href="http://www.ncbi.nlm.nih.gov/pubmed/30280640">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1113 href="https://doi.org/10.1056/NEJMoa1806640">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734059120">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d36773e1126 class=n-a></a>Dunlay SM, Givertz MM, Aguilar D, <i> et al.</i>: Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. <i>J Card Fail.</i> 2019; <b>25</b>(8): 584619. <a target=xrefwindow id=d36773e1137 href="http://www.ncbi.nlm.nih.gov/pubmed/31174952">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1140 href="https://doi.org/10.1016/j.cardfail.2019.05.007">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d36773e1149 class=n-a></a>DeFronzo RA, Norton L, Abdul-Ghani M: Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. <i>Nat Rev Nephrol.</i> 2017; <b>13</b>(1): 1126. <a target=xrefwindow id=d36773e1157 href="http://www.ncbi.nlm.nih.gov/pubmed/27941935">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1160 href="https://doi.org/10.1038/nrneph.2016.170">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d36773e1169 class=n-a></a>Carbone S, Dixon DL, Buckley LF, <i> et al.</i>: Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. <i>Mayo Clin Proc.</i> 2018; <b>93</b>(11): 16291647. <a target=xrefwindow id=d36773e1180 href="http://www.ncbi.nlm.nih.gov/pubmed/30392544">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1183 href="https://doi.org/10.1016/j.mayocp.2018.07.018">Publisher Full Text </a> | <a target=xrefwindow id=d36773e1187 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6501786">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725794423"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1196 class=n-a></a>Zinman B, Wanner C, Lachin JM, <i> et al.</i>: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>N Engl J Med.</i> 2015; <b>373</b>(22): 211728. <a target=xrefwindow id=d36773e1207 href="http://www.ncbi.nlm.nih.gov/pubmed/26378978">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1210 href="https://doi.org/10.1056/NEJMoa1504720">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725794423">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727709200"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1224 class=n-a></a>Neal B, Perkovic V, Mahaffey KW, <i> et al.</i>: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>N Engl J Med.</i> 2017; <b>377</b>(7): 644657. <a target=xrefwindow id=d36773e1235 href="http://www.ncbi.nlm.nih.gov/pubmed/28605608">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1238 href="https://doi.org/10.1056/NEJMoa1611925">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727709200">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734412764"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1251 class=n-a></a>Wiviott SD, Raz I, Bonaca MP, <i> et al.</i>: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>N Engl J Med.</i> 2019; <b>380</b>(4): 347357. <a target=xrefwindow id=d36773e1262 href="http://www.ncbi.nlm.nih.gov/pubmed/30415602">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1265 href="https://doi.org/10.1056/NEJMoa1812389">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734412764">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726105599"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1278 class=n-a></a>Fitchett D, Zinman B, Wanner C, <i> et al.</i>: Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. <i>Eur Heart J.</i> 2016; <b>37</b>(19): 152634. <a target=xrefwindow id=d36773e1289 href="http://www.ncbi.nlm.nih.gov/pubmed/26819227">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1292 href="https://doi.org/10.1093/eurheartj/ehv728">Publisher Full Text </a> | <a target=xrefwindow id=d36773e1296 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4872285">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726105599">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d36773e1309 class=n-a></a>Rdholm K, Figtree G, Perkovic V, <i> et al.</i>: Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus. <i>Circulation.</i> 2018; <b>138</b>(5): 458468. <a target=xrefwindow id=d36773e1320 href="http://www.ncbi.nlm.nih.gov/pubmed/29526832">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1323 href="https://doi.org/10.1161/CIRCULATIONAHA.118.034222">Publisher Full Text </a> | <a target=xrefwindow id=d36773e1327 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6075881">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735339165"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1336 class=n-a></a>Figtree GA, Rdholm K, Barrett TD, <i> et al.</i>: Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. <i>Circulation.</i> 2019; <b>139</b>(22): 25912593. <a target=xrefwindow id=d36773e1347 href="http://www.ncbi.nlm.nih.gov/pubmed/30882240">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1350 href="https://doi.org/10.1161/CIRCULATIONAHA.119.040057">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735339165">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735350992"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1363 class=n-a></a>Kato ET, Silverman MG, Mosenzon O, <i> et al.</i>: Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation.</i> 2019; <b>139</b>(22): 25282536. <a target=xrefwindow id=d36773e1374 href="http://www.ncbi.nlm.nih.gov/pubmed/30882238">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1377 href="https://doi.org/10.1161/CIRCULATIONAHA.119.040130">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735350992">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d36773e1391 class=n-a></a>Soga F, Tanaka H, Tatsumi K, <i> et al.</i>: Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. <i>Cardiovasc Diabetol.</i> 2018; <b>17</b>(1): 132. <a target=xrefwindow id=d36773e1402 href="http://www.ncbi.nlm.nih.gov/pubmed/30296931">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1405 href="https://doi.org/10.1186/s12933-018-0775-z">Publisher Full Text </a> | <a target=xrefwindow id=d36773e1409 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6174555">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d36773e1418 class=n-a></a>Matsutani D, Sakamoto M, Kayama Y, <i> et al.</i>: Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. <i>Cardiovasc Diabetol.</i> 2018; <b>17</b>(1): 73. <a target=xrefwindow id=d36773e1429 href="http://www.ncbi.nlm.nih.gov/pubmed/29788955">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1432 href="https://doi.org/10.1186/s12933-018-0717-9">Publisher Full Text </a> | <a target=xrefwindow id=d36773e1436 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5963148">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736624441"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1445 class=n-a></a>McMurray JJV, Solomon SD, Inzucchi SE, <i> et al.</i>: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>N Engl J Med.</i> 2019; <b>381</b>(21): 19952008. <a target=xrefwindow id=d36773e1456 href="http://www.ncbi.nlm.nih.gov/pubmed/31535829">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1459 href="https://doi.org/10.1056/NEJMoa1911303">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736624441">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d36773e1472 class=n-a></a>Ruberg FL, Grogan M, Hanna M, <i> et al.</i>: Transthyretin Amyloid Cardiomyopathy: <i>JACC</i> State-of-the-Art Review. <i>J Am Coll Cardiol.</i> 2019; <b>73</b>(22): 28722891. <a target=xrefwindow id=d36773e1486 href="http://www.ncbi.nlm.nih.gov/pubmed/31171094">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1490 href="https://doi.org/10.1016/j.jacc.2019.04.003">Publisher Full Text </a> | <a target=xrefwindow id=d36773e1493 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6724183">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d36773e1502 class=n-a></a>Gonzlez-Lpez E, Gallego-Delgado M, Guzzo-Merello G, <i> et al.</i>: Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. <i>Eur Heart J.</i> 2015; <b>36</b>(38): 258594. <a target=xrefwindow id=d36773e1513 href="http://www.ncbi.nlm.nih.gov/pubmed/26224076">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1516 href="https://doi.org/10.1093/eurheartj/ehv338">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d36773e1525 class=n-a></a>Bulawa CE, Connelly S, Devit M, <i> et al.</i>: Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. <i>Proc Natl Acad Sci U S A. </i> 2012; <b>109</b>(24): 962934. <a target=xrefwindow id=d36773e1536 href="http://www.ncbi.nlm.nih.gov/pubmed/22645360">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1539 href="https://doi.org/10.1073/pnas.1121005109">Publisher Full Text </a> | <a target=xrefwindow id=d36773e1543 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3386102">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733869893"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1553 class=n-a></a>Maurer MS, Schwartz JH, Gundapaneni B, <i> et al.</i>: Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. <i>N Engl J Med.</i> 2018; <b>379</b>(11): 10071016. <a target=xrefwindow id=d36773e1564 href="http://www.ncbi.nlm.nih.gov/pubmed/30145929">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1567 href="https://doi.org/10.1056/NEJMoa1805689">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733869893">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d36773e1580 class=n-a></a>Fire A, Xu S, Montgomery MK, <i> et al.</i>: Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i>. <i>Nature.</i> 1998; <b>391</b>(6669): 80611. <a target=xrefwindow id=d36773e1594 href="http://www.ncbi.nlm.nih.gov/pubmed/9486653">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1598 href="https://doi.org/10.1038/35888">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d36773e1607 class=n-a></a>Coelho T, Adams D, Silva A, <i> et al.</i>: Safety and efficacy of RNAi therapy for transthyretin amyloidosis. <i>N Engl J Med.</i> 2013; <b>369</b>(9): 81929. <a target=xrefwindow id=d36773e1618 href="http://www.ncbi.nlm.nih.gov/pubmed/23984729">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1621 href="https://doi.org/10.1056/NEJMoa1208760">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733576185"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1630 class=n-a></a>Adams D, Gonzalez-Duarte A, ORiordan WD, <i> et al.</i>: Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. <i>N Engl J Med.</i> 2018; <b>379</b>(1): 1121. <a target=xrefwindow id=d36773e1641 href="http://www.ncbi.nlm.nih.gov/pubmed/29972753">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1644 href="https://doi.org/10.1056/NEJMoa1716153">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733576185">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d36773e1657 class=n-a></a>Minamisawa M, Claggett B, Adams D, <i> et al.</i>: Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study. <i>JAMA Cardiol.</i> 2019; <b>4</b>(5): 466472. <a target=xrefwindow id=d36773e1668 href="http://www.ncbi.nlm.nih.gov/pubmed/30878017">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1671 href="https://doi.org/10.1001/jamacardio.2019.0849">Publisher Full Text </a> | <a target=xrefwindow id=d36773e1675 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6537803">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d36773e1684 class=n-a></a>Solomon SD, Adams D, Kristen A, <i> et al.</i>: Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. <i>Circulation.</i> 2019; <b>139</b>(4): 431443. <a target=xrefwindow id=d36773e1695 href="http://www.ncbi.nlm.nih.gov/pubmed/30586695">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1698 href="https://doi.org/10.1161/CIRCULATIONAHA.118.035831">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733576186"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e1708 class=n-a></a>Benson MD, Waddington-Cruz M, Berk JL, <i> et al.</i>: Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. <i>N Engl J Med.</i> 2018; <b>379</b>(1): 2231. <a target=xrefwindow id=d36773e1719 href="http://www.ncbi.nlm.nih.gov/pubmed/29972757">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1722 href="https://doi.org/10.1056/NEJMoa1716793">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733576186">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d36773e1735 class=n-a></a>Judge DP, Heitner SB, Falk RH, <i> et al.</i>: Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. <i>J Am Coll Cardiol.</i> 2019; <b>74</b>(3): 285295. <a target=xrefwindow id=d36773e1746 href="http://www.ncbi.nlm.nih.gov/pubmed/30885685">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1749 href="https://doi.org/10.1016/j.jacc.2019.03.012">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d36773e1758 class=n-a></a>Klip IT, Comin-Colet J, Voors AA, <i> et al.</i>: Iron deficiency in chronic heart failure: an international pooled analysis. <i>Am Heart J.</i> 2013; <b>165</b>(4): 575582.e3. <a target=xrefwindow id=d36773e1769 href="http://www.ncbi.nlm.nih.gov/pubmed/23537975">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1772 href="https://doi.org/10.1016/j.ahj.2013.01.017">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d36773e1781 class=n-a></a>Yeo TJ, Yeo PSD, Ching-Chiew Wong R, <i> et al.</i>: Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. <i>Eur J Heart Fail.</i> 2014; <b>16</b>(10): 11251132. <a target=xrefwindow id=d36773e1792 href="http://www.ncbi.nlm.nih.gov/pubmed/25208495">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1795 href="https://doi.org/10.1002/ejhf.161">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d36773e1804 class=n-a></a>von Haehling S, Gremmler U, Krumm M, <i> et al.</i>: Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry. <i>Clin Res Cardiol.</i> 2017; <b>106</b>(6): 436443. <a target=xrefwindow id=d36773e1815 href="http://www.ncbi.nlm.nih.gov/pubmed/28229219">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1818 href="https://doi.org/10.1007/s00392-016-1073-y">Publisher Full Text </a> | <a target=xrefwindow id=d36773e1822 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5442200">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d36773e1831 class=n-a></a>Jankowska EA, Rozentryt P, Witkowska A, <i> et al.</i>: Iron deficiency: an ominous sign in patients with systolic chronic heart failure. <i>Eur Heart J.</i> 2010; <b>31</b>(15): 187280. <a target=xrefwindow id=d36773e1842 href="http://www.ncbi.nlm.nih.gov/pubmed/20570952">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1845 href="https://doi.org/10.1093/eurheartj/ehq158">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d36773e1855 class=n-a></a>Martens P, Verbrugge FH, Nijst P, <i> et al.</i>: Limited contractile reserve contributes to poor peak exercise capacity in iron-deficient heart failure. <i>Eur J Heart Fail.</i> 2018; <b>20</b>(4): 806808. <a target=xrefwindow id=d36773e1866 href="http://www.ncbi.nlm.nih.gov/pubmed/28925093">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1869 href="https://doi.org/10.1002/ejhf.938">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d36773e1878 class=n-a></a>Tkaczyszyn M, Drozd M, Wgrzynowska-Teodorczyk K, <i> et al.</i>: Depleted iron stores are associated with inspiratory muscle weakness independently of skeletal muscle mass in men with systolic chronic heart failure. <i>J Cachexia Sarcopenia Muscle.</i> 2018; <b>9</b>(3): 547556. <a target=xrefwindow id=d36773e1889 href="http://www.ncbi.nlm.nih.gov/pubmed/29573220">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1892 href="https://doi.org/10.1002/jcsm.12282">Publisher Full Text </a> | <a target=xrefwindow id=d36773e1896 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5989741">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d36773e1905 class=n-a></a>Enjuanes C, Klip IT, Bruguera J, <i> et al.</i>: Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. <i>Int J Cardiol.</i> 2014; <b>174</b>(2): 26875. <a target=xrefwindow id=d36773e1916 href="http://www.ncbi.nlm.nih.gov/pubmed/24768464">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1919 href="https://doi.org/10.1016/j.ijcard.2014.03.169">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d36773e1928 class=n-a></a>Melenovsky V, Petrak J, Mracek T, <i> et al.</i>: Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. <i>Eur J Heart Fail.</i> 2017; <b>19</b>(4): 522530. <a target=xrefwindow id=d36773e1939 href="http://www.ncbi.nlm.nih.gov/pubmed/27647766">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1942 href="https://doi.org/10.1002/ejhf.640">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d36773e1951 class=n-a></a>Hoes MF, Grote Beverborg N, Kijlstra JD, <i> et al.</i>: Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. <i>Eur J Heart Fail.</i> 2018; <b>20</b>(5): 910919. <a target=xrefwindow id=d36773e1962 href="http://www.ncbi.nlm.nih.gov/pubmed/29484788">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1965 href="https://doi.org/10.1002/ejhf.1154">Publisher Full Text </a> | <a target=xrefwindow id=d36773e1969 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5993224">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d36773e1978 class=n-a></a>Haddad S, Wang Y, Galy B, <i> et al.</i>: Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. <i>Eur Heart J.</i> 2017; <b>38</b>(5): 362372. <a target=xrefwindow id=d36773e1989 href="http://www.ncbi.nlm.nih.gov/pubmed/27545647">PubMed Abstract </a> | <a target=xrefwindow id=d36773e1992 href="https://doi.org/10.1093/eurheartj/ehw333">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d36773e2002 class=n-a></a>Jankowska EA, Tkaczyszyn M, Suchocki T, <i> et al.</i>: Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: A meta-analysis of randomized controlled trials. <i>Eur J Heart Fail.</i> 2016; <b>18</b>(7): 78695. <a target=xrefwindow id=d36773e2013 href="http://www.ncbi.nlm.nih.gov/pubmed/26821594">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2016 href="https://doi.org/10.1002/ejhf.473">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d36773e2025 class=n-a></a>van Veldhuisen DJ, Ponikowski P, van der Meer P, <i> et al.</i>: Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation.</i> 2017; <b>136</b>(15): 13741383. <a target=xrefwindow id=d36773e2036 href="http://www.ncbi.nlm.nih.gov/pubmed/28701470">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2039 href="https://doi.org/10.1161/CIRCULATIONAHA.117.027497">Publisher Full Text </a> | <a target=xrefwindow id=d36773e2043 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5642327">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d36773e2052 class=n-a></a>Charles-Edwards G, Amaral N, Sleigh A, <i> et al.</i>: Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation.</i> 2019; <b>139</b>(21): 23862398. <a target=xrefwindow id=d36773e2063 href="http://www.ncbi.nlm.nih.gov/pubmed/30776909">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2066 href="https://doi.org/10.1161/CIRCULATIONAHA.118.038516">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727617606"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e2075 class=n-a></a>Lewis GD, Malhotra R, Hernandez AF, <i> et al.</i>: Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. <i>JAMA.</i> 2017; <b>317</b>(19): 19581966. <a target=xrefwindow id=d36773e2086 href="http://www.ncbi.nlm.nih.gov/pubmed/28510680">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2089 href="https://doi.org/10.1001/jama.2017.5427">Publisher Full Text </a> | <a target=xrefwindow id=d36773e2093 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5703044">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727617606">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d36773e2106 class=n-a></a>Moretti D, Goede JS, Zeder C, <i> et al.</i>: Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. <i>Blood.</i> 2015; <b>126</b>(17): 19819. <a target=xrefwindow id=d36773e2117 href="http://www.ncbi.nlm.nih.gov/pubmed/26289639">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2120 href="https://doi.org/10.1182/blood-2015-05-642223">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732002697"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e2129 class=n-a></a>Stoffel NU, Cercamondi CI, Brittenham G, <i> et al.</i>: Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. <i>Lancet Haematol.</i> 2017; <b>4</b>(11): e524e533. <a target=xrefwindow id=d36773e2140 href="http://www.ncbi.nlm.nih.gov/pubmed/29032957">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2143 href="https://doi.org/10.1016/S2352-3026(17)30182-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732002697">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d36773e2157 class=n-a></a>Troughton RW, Frampton CM, Brunner-La Rocca HP, <i> et al.</i>: Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: An individual patient meta-analysis. <i>Eur Heart J.</i> 2014; <b>35</b>(23): 155967. <a target=xrefwindow id=d36773e2168 href="http://www.ncbi.nlm.nih.gov/pubmed/24603309">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2171 href="https://doi.org/10.1093/eurheartj/ehu090">Publisher Full Text </a> | <a target=xrefwindow id=d36773e2175 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4057643">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729075176"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e2184 class=n-a></a>Felker GM, Anstrom KJ, Adams KF, <i> et al.</i>: Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. <i>JAMA.</i> 2017; <b>318</b>(8): 713720. <a target=xrefwindow id=d36773e2195 href="http://www.ncbi.nlm.nih.gov/pubmed/28829876">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2198 href="https://doi.org/10.1001/jama.2017.10565">Publisher Full Text </a> | <a target=xrefwindow id=d36773e2202 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5605776">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729075176">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d36773e2215 class=n-a></a>Davarzani N, Sanders-van Wijk S, Karel J, <i> et al.</i>: N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF. <i>J Card Fail.</i> 2017; <b>23</b>(5): 382389. <a target=xrefwindow id=d36773e2226 href="http://www.ncbi.nlm.nih.gov/pubmed/28232046">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2229 href="https://doi.org/10.1016/j.cardfail.2017.02.001">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d36773e2238 class=n-a></a>Yancy CW, Jessup M, Bozkurt B, <i> et al.</i>: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation.</i> 2013; <b>128</b>(16): e240327. <a target=xrefwindow id=d36773e2249 href="http://www.ncbi.nlm.nih.gov/pubmed/23741058">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2252 href="https://doi.org/10.1161/CIR.0b013e31829e8776">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d36773e2261 class=n-a></a>Ponikowski P, Voors AA, Anker SD, <i> et al.</i>: 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. <i>Rev Esp Cardiol (Engl Ed).</i> 2016; <b>69</b>(12): 1167. <a target=xrefwindow id=d36773e2272 href="http://www.ncbi.nlm.nih.gov/pubmed/27894487">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2275 href="https://doi.org/10.1016/j.rec.2016.11.005">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9060956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36773e2284 class=n-a></a>Abraham WT, Adamson PB, Bourge RC, <i> et al.</i>: Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. <i>Lancet.</i> 2011; <b>377</b>(9766): 65866. <a target=xrefwindow id=d36773e2295 href="http://www.ncbi.nlm.nih.gov/pubmed/21315441">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2298 href="https://doi.org/10.1016/S0140-6736(11)60101-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9060956">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d36773e2312 class=n-a></a>Adamson PB, Abraham WT, Bourge RC, <i> et al.</i>: Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. <i>Circ Heart Fail.</i> 2014; <b>7</b>(6): 93544. <a target=xrefwindow id=d36773e2323 href="http://www.ncbi.nlm.nih.gov/pubmed/25286913">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2326 href="https://doi.org/10.1161/CIRCHEARTFAILURE.113.001229">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d36773e2335 class=n-a></a>Heywood JT, Jermyn R, Shavelle D, <i> et al.</i>: Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor. <i>Circulation.</i> 2017; <b>135</b>(16): 15091517. <a target=xrefwindow id=d36773e2346 href="http://www.ncbi.nlm.nih.gov/pubmed/28219895">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2349 href="https://doi.org/10.1161/CIRCULATIONAHA.116.026184">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d36773e2358 class=n-a></a>Abraham J, Bharmi R, Jonsson O, <i> et al.</i>: Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis. <i>JAMA Cardiol.</i> 2019; <b>4</b>(6): 556563. <a target=xrefwindow id=d36773e2369 href="http://www.ncbi.nlm.nih.gov/pubmed/31090869">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2372 href="https://doi.org/10.1001/jamacardio.2019.1384">Publisher Full Text </a> | <a target=xrefwindow id=d36773e2376 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6537799">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d36773e2385 class=n-a></a>Costanzo MR, Stevenson LW, Adamson PB, <i> et al.</i>: Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring. <i>JACC Heart Fail.</i> 2016; <b>4</b>(5): 33344. <a target=xrefwindow id=d36773e2396 href="http://www.ncbi.nlm.nih.gov/pubmed/26874388">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2399 href="https://doi.org/10.1016/j.jchf.2015.11.011">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d36773e2408 class=n-a></a>Givertz MM, Stevenson LW, Costanzo MR, <i> et al.</i>: Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. <i>J Am Coll Cardiol.</i> 2017; <b>70</b>(15): 18751886. <a target=xrefwindow id=d36773e2419 href="http://www.ncbi.nlm.nih.gov/pubmed/28982501">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2422 href="https://doi.org/10.1016/j.jacc.2017.08.010">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d36773e2431 class=n-a></a>Jermyn R, Alam A, Kvasic J, <i> et al.</i>: Hemodynamic-guided heart-failure management using a wireless implantable sensor: Infrastructure, methods, and results in a community heart failure disease-management program. <i>Clin Cardiol.</i> 2017; <b>40</b>(3): 170176. <a target=xrefwindow id=d36773e2442 href="http://www.ncbi.nlm.nih.gov/pubmed/27878990">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2445 href="https://doi.org/10.1002/clc.22643">Publisher Full Text </a> | <a target=xrefwindow id=d36773e2449 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6490562">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d36773e2459 class=n-a></a>Buckley LF, Cooper IM, Navarro-Velez K, <i> et al.</i>: Burden of nursing activities during hemodynamic monitoring of heart failure patients. <i>Heart Lung.</i> 2018; <b>47</b>(4): 304307. <a target=xrefwindow id=d36773e2470 href="http://www.ncbi.nlm.nih.gov/pubmed/29801671">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2473 href="https://doi.org/10.1016/j.hrtlng.2018.05.001">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d36773e2482 class=n-a></a>Singh R, Varjabedian L, Kaspar G, <i> et al.</i>: CardioMEMS in a Busy Cardiology Practice: Less than Optimal Implementation of a Valuable Tool to Reduce Heart Failure Readmissions. <i>Cardiol Res Pract.</i> 2018; <b>2018</b>: 4918757. <a target=xrefwindow id=d36773e2493 href="http://www.ncbi.nlm.nih.gov/pubmed/30524758">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2496 href="https://doi.org/10.1155/2018/4918757">Publisher Full Text </a> | <a target=xrefwindow id=d36773e2500 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6247721">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d36773e2509 class=n-a></a>Sandhu AT, Goldhaber-Fiebert JD, Owens DK, <i> et al.</i>: Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure. <i>JACC Heart Fail.</i> 2016; <b>4</b>(5): 36875. <a target=xrefwindow id=d36773e2520 href="http://www.ncbi.nlm.nih.gov/pubmed/26874380">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2523 href="https://doi.org/10.1016/j.jchf.2015.12.015">Publisher Full Text </a> | <a target=xrefwindow id=d36773e2527 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4851610">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d36773e2536 class=n-a></a>Ollendorf DA, Sandhu AT, Pearson SD: CardioMEMS HF for the Management of Heart Failure-Effectiveness and Value. <i>JAMA Intern Med.</i> 2016; <b>176</b>(10): 15511552. <a target=xrefwindow id=d36773e2544 href="http://www.ncbi.nlm.nih.gov/pubmed/27599253">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2547 href="https://doi.org/10.1001/jamainternmed.2016.5467">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d36773e2556 class=n-a></a>Veenis JF, Manintveld OC, Constantinescu AA, <i> et al.</i>: Design and rationale of haemodynamic guidance with CardioMEMS in patients with a left ventricular assist device: the HEMO-VAD pilot study. <i>ESC Heart Fail.</i> 2019; <b>6</b>(1): 194201. <a target=xrefwindow id=d36773e2567 href="http://www.ncbi.nlm.nih.gov/pubmed/30614639">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2570 href="https://doi.org/10.1002/ehf2.12392">Publisher Full Text </a> | <a target=xrefwindow id=d36773e2574 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6351888">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d36773e2583 class=n-a></a>Kilic A, Katz JN, Joseph SM, <i> et al.</i>: Changes in pulmonary artery pressure before and after left ventricular assist device implantation in patients utilizing remote haemodynamic monitoring. <i>ESC Heart Fail.</i> 2019; <b>6</b>(1): 138145. <a target=xrefwindow id=d36773e2594 href="http://www.ncbi.nlm.nih.gov/pubmed/30350926">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2597 href="https://doi.org/10.1002/ehf2.12373">Publisher Full Text </a> | <a target=xrefwindow id=d36773e2601 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6352918">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d36773e2611 class=n-a></a>Khan Z, Gholkar G, Tolia S, <i> et al.</i>: Effect of sacubitril/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction. <i>Int J Cardiol.</i> 2018; <b>271</b>: 169173. <a target=xrefwindow id=d36773e2622 href="http://www.ncbi.nlm.nih.gov/pubmed/30093137">PubMed Abstract </a> | <a target=xrefwindow id=d36773e2625 href="https://doi.org/10.1016/j.ijcard.2018.03.093">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 20 Dec 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-2134&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-2134&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Pharmacy, Brigham and Women's Hospital, Boston, USA<br/> <sup>2</sup> Division of Cardiovascular Medicine, Brigham and Women&rsquo;s Hospital, Boston, USA<br/> <p> <div class=margin-bottom> Leo F Buckley <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation </div> <div class=margin-bottom> Amil M Shah <br/> <span>Roles: </span> Conceptualization, Supervision, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-2134/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 20 Dec 2019, 8:2134 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.20447.1">https://doi.org/10.12688/f1000research.20447.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2019 Buckley LF and Shah AM. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=22478 data-id=20447 data-downloads="" data-views="" data-scholar="10.12688/f1000research.20447.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-2134/v1/pdf?article_uuid=3e4a82e9-a09d-4180-8984-bd21341c11f5" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.20447.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Buckley LF and Shah AM. Recent advances in the treatment of chronic heart failure [version 1; peer review: 3 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2134 (<a href="https://doi.org/10.12688/f1000research.20447.1" target=_blank>https://doi.org/10.12688/f1000research.20447.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=20447 id=mobile-track-article-signin-20447 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/20447?target=/articles/8-2134"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=22478 /> <input name=articleId type=hidden value=20447 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Ferdinando Iellamo</strong>, Research Institute San Raffaele Pisana, Italy; University of Rome Tor Vergata, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Chim C Lang</strong>, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital & Medical School, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Jawahar L Mehta</strong>, Division of Cardiology, Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 20 Dec 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-2134&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-2134&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=61683-57912></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=53986-57913></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=61684-57914></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-2134/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>20 Dec 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Ferdinando Iellamo</strong>, Research Institute San Raffaele Pisana, Italy; University of Rome Tor Vergata, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Chim C Lang</strong>, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital & Medical School, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jawahar L Mehta</strong>, Division of Cardiology, Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-2134&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-2134/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the treatment of chronic...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-2134/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-2134/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-2134/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Buckley LF and Shah AM');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-2134/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-2134",
            templates : {
                twitter : "Recent advances in the treatment of chronic heart failure. Buckley LF and Shah AM, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-2134/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the treatment of chronic heart failure", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the treatment of chronic heart failure", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/20447/22478")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "22478");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "57912": 1,
                           "57913": 0,
                           "57914": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "47d21ef3-5f65-4c87-9cec-06a949b84dd7";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2134.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2134.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2134.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-2134.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-2134.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>